Samsung Bioepis represents the marriage of an Asian company and a Western drugmaker with a focus on biosimilars. Now, two other players are reportedly considering …
China unveiled new inclusions in its national reimbursement drug list, featuring novel therapies from Biogen, Pfizer, Eli Lilly and more. Partners Biocon and Viatris are …
It’s official: Biocon and Viatris have launched their historic interchangeable insulin biosimilar, Semglee. The drug, which references Sanofi’s blockbuster diabetes med Lantus, will roll out …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
